报告包含2011-2013年中国医疗行业发展分析、2011-2013年农村医疗行业分析、2011-2013年农村医疗体制发展分析、2011-2013年新型农村合作医疗发发展、2011-2013年农村商业医疗保险的发展、2011-2014年主要区域农村医疗行业分析、2011-2013年农村医疗市场的发展、2011-2013年农村医疗机构的建设、农村医疗行业投资及前景分析。

China's market has been growing at a phenomenal pace, fuelled by the country's seemingly endless capacity for strong economic growth, and the government's ongoing desire to put healthcare spending on a more comprehensive and equitable footing. Since 2008, the market has more than doubled in value to reach an estimated US$16.1bn in 2013. This represents a CAGR of 21.1%. In per capita terms, spending has risen from US$4.6 in 2008 to US$11.6 in 2013.

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面对医药行业进行了分析评论。

报告从产业动态、产业分析、技术趋势、企业跟踪、地方动向等几个方面对生物科技产业进行了分析评论。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

7月，医药行业产销规模增长有所放缓。其中，中成药产量环比下降11.96%，中西药品类零售总额环比下降4.50%。在药品价格调控的引导下，医药品价格增长稳中趋缓，7月医药制造业工业品出厂价格指数为100.68点，比上月下滑0.041点。上半年，受内外需求增长乏力、医保控费、环保支出增大等因素影响，医药行业利润增速放缓，实现利润总额1056.19亿元，同比增长14.88%，较上年同期下降1.71个百分点。下半年，随着各省药品招标进程逐步加快，下游需求将回暖，再加上行业政策逐渐明朗，企业将逐渐走出新版GMP认证带来的负面影响，预计医药行业发展速度将有所上升。

The Center for Medicare Management at the Centers for Medicare and Medicaid Services (CMS) requested this report from the Technology Assessment Program (TAP) at the Agency for Healthcare Research and Quality (AHRQ). AHRQ assigned this report to the ECRI Institute Evidence-based Practice Center (EPC) (Contract Number: HHSA 290-2007-10063).

Prostate cancer (PCa) is one of the most common malignancies in men, and is a complex disease in its development and response to therapy. Loss of tumor suppressors genes is a frequent initiating event that is irreversible, whereas tumor promotion and progression are susceptible to modulation, which provides a rationale for therapeutic intervention. Tumor promotion is highly regulated by the interaction between initiated cells and their microenviroment and inflammation is a frequent and important tumor promoter. However, despite the strong evidence for an inflammatory component to the pathology of PCa, the process of inflammation and the related signaling pathways are largely unknown. Therefore, a better understanding of the molecular mechanisms that govern the inflammatory response and its impact on PCa progression is of paramount importance in developing novel therapies for PCa. Here we report the identification of a novel network between tumor suppressors: Par-4, PKCzeta and PTEN and the characterization of the inflammatory response unleashed upon their loss. Importantly, our results also demonstrate that inflammation is not only secondarily associated to carcinogenesis but it is an important contributing factor in tumor promotion.

本刊以七大战略性新兴产业——高端装备制造、节能环保、新能源、新材料、新能源汽车、生物、新一代信息技术为研究重点，关注国家高层和各部委的动态，剖析国家和地方的新兴产业政策。本刊设有政策导读、领导讲话、七大战略性新兴产业本周国内外行业动态和重点企业新闻、投资专题四大板块，能够实时监测新兴产业和重点企业动态，把握新兴产业发展方向，研究发展重点，寻求发展机遇。